A study published in the July 23 issue of Nature Medicine found that patients with chronic myelogenous leukemia (CML) receiving imatinib (Gleevec, Novartis) are at increased risk for heart failure. Researchers found that the ABL enzyme that is turned off by imatinib is actually a necessary component in maintaining the health of cardiac muscle cells.
Replacement enzyme idursulfase (Elaprase, Shire Human Genetic Therapies) has been approved by the FDA as the first treatment for Hunter syndrome (mucopolysaccharidosis II), a rare disease in which the body cannot produce iduronate-2-sulfatase. The enzyme is necessary to break down complex sugars produced in the body, and its deficiency can lead to growth delay, coarsening of facial features, and joint stiffness
A recently released report from the National Institute on Drug Abuse (NIDA) shows that effective treatment of drug abuse and addiction can take a bite out of crime and save communities money. Principles of Drug Abuse Treatment for Criminal Justice Populations is based on a review of the scientific literature on drug abuse treatment and criminal behavior, according to NIDA.
The Government Accountability Office has found that four genetic tests purchased from four Web sites mislead consumers by making predictions that are medically unproven and so ambiguous that they do not provide meaningful information to consumers. GAO purchased tests from four Web sites and created fictitious consumers by submitting for analysis 12 DNA samples from a female and two samples from an unrelated male.
CollaGenex Pharmaceuticals received approval from the Food & Drug Administration in late May to market Oracea. According to the company, this is the first systemically delivered treatment for the treatment of rosacea. Affecting an estimated 14 million adults in the United States, rosacea is a dermatological condition characterized by papules and pustules, erythema, and telangiectasia.
Wal-Mart has agreed to sell Barr Pharmaceutical's Plan B emergency contraception in Connecticut. Wal-Mart will continue to allow pharmacists to refuse to fill the prescription and to refer customers to other pharmacies.
Disetronic Medical Systems and the FDA announced a voluntary nationwide recall of the Disetronic D-TRONplus Power Packs, which power the D-TRON Insulin Pump. There is the potential that the power pack could shut down the D-TRONplus Insulin Pump without any warning.
Pharmacists may wake up to a rise in prescriptions for insomnia medication Rozerem (ramelteon), as Takeda Pharmaceuticals North America gets set to launch its first DTC campaign for the medication. The campaign, which includes print, on-line, and broadcast ads, carries the theme "Your Dreams Miss You."
California Senate Bill 1305 has been passed. The new law requires the proper disposal of home-generated sharps waste (syringes, needles, lancets, etc.) and acknowledges mail-back programs as one of the most convenient alternatives for the collection and destruction of home-generated sharps.
Illinois Gov. Blagojevich has launched a patient safety initiative aimed at reducing medication-related errors by requiring all healthcare providers to use "e-prescribing" paperless doctor prescriptions. The initiative creates a division of patient safety within the Illinois Department of Public Health focused on reducing medical mistakes, developing standard medication practices to reduce adverse drug interactions, and creating on-line physician databases so patients can check out their doctors.
The House and Senate are considering a bill that would force many U.S. military families to fill most of their prescriptions through mail order. The TRICARE provisions of the Defense Authorization Act are headed for a House-Senate conference after different versions of the bill passed in each chamber.
Complaints from NCPA members have been steadily building over low maximum allowable cost (MAC) reimbursement from Express Scripts for generic Zocor. According to NCPA, it has received numerous reports that Express Scripts, one of the largest PBMs in the country, has set a MAC for simvastatin at approximately two-thirds of the pharmacy acquisition price.
Wal-Mart has launched a new ad campaign to promote its pharmacy departments. The effort includes TV, radio, print, outdoor, on-line, in-store, and direct-mail components.
The American Liver Foundation (ALF) has issued a warning based on a recent study dealing with the effects of high doses of acetaminophen on the liver. The study, published recently in the Journal of the American Medical Association, showed that healthy adults who took the maximum recommended dose of acetaminophen for two weeks had drastically increased liver enzyme levels, which could lead to liver damage.
SmartCare Family Medical Centers, a Colorado-based operator of retail healthcare centers, has signed a partnership agreement with the Fred Meyer Division of the Kroger Co. to open its SmartCare Centers inside sports stores located in Alaska, Idaho, Oregon, and Washington. SmartCare Centers will open centers in Seattle this fall.
Bayer Healthcare has announced the launch of a program designed for patients with hemophilia A. The Kogenate FS with Bio-Set Free Trial Program will allow enrollees to receive up to six free infusions of the product delivered to their home or location of choice.
Pharmacist William Schobert, who used to work at Nugent's Apothecary, in Medford, N.J., could face up to 20 years in prison for allegedly creating more than 500 false prescriptions for himself and his family members. Investigators have charged that he sought reimbursement to the tune of $80,000 for the fake claims over a two-year period from his insurer.
Results from two recent studies have led the FDA to notify healthcare professionals and consumers to new concerns about treating pregnant women who take antidepressants. One study showed that women who stopped taking their antidepressants were five times more likely to experience a relapse of their depression during pregnancy compared with those who continued to take the medication.
USP wants input from healthcare practitioners and other interested parties regarding the proposed revisions.
Medication reconciliation is back on the front burner. The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has expanded its existing National Patient Safety Goal on medication reconciliation for 2007.
The FDA wants to alert healthcare providers about name confusion between Mucomyst and Mucinex. These errors may be occurring due to the increased off-label use of Mucomyst for the prevention of acute renal failure associated with radiographic contrast media. To date, all errors reported to the FDA MedWatch system occurred during the prescription order, transcription, and product selection phases of inpatient medication use. No adverse events were reported as a result of these errors.
The generic pharmaceutical industry has been at odds with the Food & Drug Administration over several key issues lately, including authorized generics, facilitating the development of more generic agents, and approving generic biopharmaceuticals. At a recent conference in New York City sponsored by the Pharmaceutical Care Management Association (PCMA), Scott Gottlieb, M.D., deputy commissioner for medical and scientific affairs at FDA, attempted to clarify the agency's position on several hot-button topics.
When the Governor signed the legislation in May, New Hampshire became, by at least one count, the 41st state to permit pharmacists to enter collaborative practice agreements with physicians. But no one knows for sure how many pharmacists are taking advantage of the professional privilege.
Reflecting the economic consequences of a manpower shortage, the median total compensation of staff pharmacists is pushing six figures, according to the latest survey from Mercer Human Resource Consulting.
There are people who actually schedule regular doctor visits as social events.
At the American Academy of Neurology's (AAN) 58th annual meeting in April, new guidelines were released for the diagnosis and treatment of Parkinson's disease (PD). The recommendations were later published in the April 11, 2006, issue of Neurology as four separate practice parameters.
Women now have the option of being immunized against cervical cancer following approval of Merck's Gardasil. Roughly 6.2 million Americans become infected with genital human papillomavirus (HPV) each year, and more than 50% of all sexually active persons become infected at some point. HPV is the most common sexually transmitted infection in the United States. While the body's immune system clears the virus in most women, some go on to develop cervical abnormalities that can lead to cancer. Cervical cancer is the second most common cause of cancer death in women, with roughly 470,000 new cases and 233,000 deaths occurring each year worldwide.
The Food & Drug Administration recently approved three generic versions of simvastatin (Zocor, Merck), the largest-selling drug yet to be opened to generic competition. For the next 180 days, Teva will have exclusive rights to sell the 5-, 10-, 20-, and 40-mg dosages of simvastatin and Ranbaxy will have the rights to sell the 80-mg dosage. In addition, Dr. Reddy's Laboratories will sell all five dosages under an agreement with Merck to be the authorized generic manufacturer of the drug.
NABP has launched its Pharmacy Authenticated Licensure Service (PALS) program providing licensure authentication of pharmacists and on-line pharmacies to state boards and the public. PALS provides a directory of licensed pharmacies and pharmacists-in-charge. Authenticated on-line pharmacies will be issued a hyperlink that users can click on to go to NABP's PALS site for details.